AUCATZYL ramping fast in adult ALL with autoimmune expansion bets ahead; commercial sustainability determines whether the platform thesis holds

Autolus is a commercial-stage cell therapy company with an approved treatment for adult acute lymphoblastic leukemia and early-stage programs in autoimmune diseases that are not yet approved.

AUCATZYL (obecabtagene autoleucel) posted $45M in Q2 2026, up 119% year-over-year, with gross margin reaching 55%, marking a structural shift from development-stage burn to commercial-stage leverage. Whether this thesis compounds depends on AUCATZYL sustaining revenue growth against approved CD19 CAR-Ts Kymriah and Tecartus while funding obe-cel's autoimmune expansion into lupus and progressive MS. The autoimmune pivot is early Phase 1 with no efficacy readout yet, and the EU launch remains on hold pending pricing resolution, leaving two meaningful execution risks open simultaneously.